List of Excipients in API RIVAROXABAN
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing RIVAROXABAN
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| A-S Medication Solutions | XARELTO | rivaroxaban | 50090-3625 | CELLULOSE, MICROCRYSTALLINE | 2025-05-13 |
| A-S Medication Solutions | XARELTO | rivaroxaban | 50090-3625 | CROSCARMELLOSE SODIUM | 2025-05-13 |
| A-S Medication Solutions | XARELTO | rivaroxaban | 50090-3625 | FERRIC OXIDE RED | 2025-05-13 |
| A-S Medication Solutions | XARELTO | rivaroxaban | 50090-3625 | HYPROMELLOSE | 2025-05-13 |
| A-S Medication Solutions | XARELTO | rivaroxaban | 50090-3625 | LACTOSE MONOHYDRATE | 2025-05-13 |
| A-S Medication Solutions | XARELTO | rivaroxaban | 50090-3625 | MAGNESIUM STEARATE | 2025-05-13 |
| A-S Medication Solutions | XARELTO | rivaroxaban | 50090-3625 | POLYETHYLENE GLYCOL 3350 | 2025-05-13 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for RIVAROXABAN
Excipient focus: CELLULOSE, MICROCRYSTALLINE
RIVAROXABAN drug variants containing CELLULOSE, MICROCRYSTALLINE
RIVAROXABAN drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
RIVAROXABAN drug variants containing CROSCARMELLOSE SODIUM
RIVAROXABAN drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
RIVAROXABAN drug variants containing FERRIC OXIDE RED
RIVAROXABAN drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Pharmaceuticals Inc | rivaroxaban | 50458-577 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
RIVAROXABAN drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Pharmaceuticals Inc | rivaroxaban | 50458-577 |
| >Company | >Ingredient | >NDC |
RIVAROXABAN drug variants not containing FERRIC OXIDE YELLOW
Excipient focus: HYPROMELLOSE
RIVAROXABAN drug variants containing HYPROMELLOSE
RIVAROXABAN drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
RIVAROXABAN drug variants containing LACTOSE MONOHYDRATE
RIVAROXABAN drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
RIVAROXABAN drug variants containing MAGNESIUM STEARATE
RIVAROXABAN drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
RIVAROXABAN drug variants containing POLYETHYLENE GLYCOL 3350
RIVAROXABAN drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
RIVAROXABAN drug variants containing SODIUM LAURYL SULFATE
RIVAROXABAN drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
RIVAROXABAN drug variants containing TITANIUM DIOXIDE
RIVAROXABAN drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
